Table 1 summarizes the characteristics and structural formulae of the most widely used and new PI3K inhibitors. Of note, only a few of these candidates, including BKM120, XL147, and XL765, have thus far entered clinical trials for the treatment of GBM [146,147] (Table 1). This evidence concerns the gene PIK3CD and glioblastoma.